PRDM2 and ovarian carcinoma: RIZ1 displays strong tumor suppressive activities, and loss-of-function mutation or deletion, and altered DNA methylation of RIZ1 have been associated with the progression of various cancers, such as ovarian carcinoma, lymphomas, colorectal cancer and glioma (8–11).